Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium’s next-generation therapeutic candidates, engineered to deliver payloads within the tumor microenvironment.
“Prokarium is designing the perfect bacteria to be the next cancer immunotherapy, and we believe leveraging Salmonella’s unique biology will allow us to combine a powerful innate approach with a tailored adaptive response,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “This agreement will significantly expand our R&D capabilities and will further deepen our immunotherapy pipeline.”
This new multi-year agreement builds on work between Prokarium and London Biofoundry that was initiated in 2020 and will further expand Prokarium’s operations. The team from Imperial’s and SynbiCITE’s London Biofoundry specializes in the design, engineering and functional characterisation of synthetic DNA and organisms.
“Prokarium has uniquely positioned their Salmonella platform as an innovative immunotherapy approach for the treatment of solid tumors, and we are excited to support their efforts in pioneering the cancer treatment paradigm shift from synthetic chemistry to synthetic biology,” said Marko Storch, PhD, Head of Synthetic Biology and Automation. “At the London Biofoundry, we developed a cutting-edge SynBio stack and the expertise to collaborate with researchers and biotechs to advance their R&D. We are thrilled to leverage our leading research capabilities to support the development of Prokarium’s new class of medicines in oncology.”
About the London Biofoundry
The London Biofoundry provides a suite of state-of-the-art robotic equipment and expertise supporting automated end-to-end design, construction, and validation of large gene constructs and biological systems. For more information visit www.londonbiofoundry.org
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. For more information visit http://www.imperial.ac.uk/
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005069/en/
Contact information
Contacts
For Prokarium
Kristen Albright
Chief Executive Officer
kristen.albright@prokarium.com
www.prokarium.com
For media
MacDougall Advisors
Matthew Corcoran
+1 781-235-3060
prokarium@macdougall.bio
www.macdougall.bio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LSEG Launches Digital Markets Infrastructure Platform for Private Funds, and Facilitates First Transaction15.9.2025 10:25:00 EEST | Press release
LSEG today announces that it has launched its Digital Markets Infrastructure (“DMI”) platform for private funds and facilitated its first transaction. DMI, which is powered by Microsoft Azure, will deliver blockchain-powered scale and efficiencies for the full asset lifecycle – from issuance, tokenisation and distribution to post trade asset settlement and servicing, across multiple asset classes. LSEG will ensure that this platform is interoperable with current market solutions in distributed ledger technology as well as traditional finance, fully utilising a range of the group's products and services, including Workspace. Developed in collaboration with Microsoft, DMI is aligned with LSEG’s goal of being the first global exchange group to support customers across the full funding continuum, alongside other group initiatives such as the Private Securities Market. Private funds is the first asset class to benefit from the DMI platform, with expansion to additional asset classes planned
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 202515.9.2025 10:15:00 EEST | Press release
DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915690916/en/ Findings will demonstrate how CGM can reduce neonatal complications linked to gestational diabetes more effectively than fingersticks. “Each year, EASD provides a high-profile opportunity to highlight our latest product innovations and new clinical data that demonstrates how Dexcom glucose biosensing technology can empower people with all types of diabetes across the globe to take control of their health, while reinforcing Dexcom CGM as a cost-effective solution for diabetes management,” said Jake Leach, president and chief operating offic
Komoot Unveils Modern Design as Part of Ambitious Product Roadmap15.9.2025 10:00:00 EEST | Press release
Komoot, the leading outdoor app, is rolling out a fresh new design: The experience is currently live for Web users worldwide, with Mobile slated for release by the end of September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915468295/en/ The updated design—the first in a series of major initiatives outlined within komoot’s ambitious new roadmap—introduces a refreshed look and includes significant improvements to the user journey to deliver a more intuitive and enjoyable experience overall. At the same time, komoot’s core navigation and workflows remain the same: The result is a modern, intuitive design that still feels familiar to returning users. The most notable changes include: A contemporary design. The new look introduces several refreshed design elements—such as color palette, fonts, icons, and illustrations—to elevate and modernize the overall komoot brand and user experience. A clearer and more intuitive stru
Dotfile Launches Autonomy: Self-Decisioning AI Agent for KYB Compliance15.9.2025 10:00:00 EEST | Press release
Dotfile, Europe’s leading AI‑powered compliance operating system, today announced Dotfile Autonomy, the industry‑first fully autonomous AI platform for Know Your Business (KYB) case review. Autonomy enables fintechs and financial institutions to fully automate routine KYB/AML workflows while maintaining regulatory oversight and end‑to‑end auditability. Self-Decisioning Technology Dotfile Autonomy debuts a sophisticated multi-agent AI architecture, combining a central orchestrator with specialized review agents. The system automatically analyzes cases, determines automation levels, and processes routine compliance reviews without the need for human intervention, escalating only complex cases to human reviewers. Vasco Alexandre, Cofounder and CEO of Dotfile, commented: “Our approach delivers huge efficiency gains, while keeping humans in the loop. We think this is the winning combination for an AI that is trusted by our clients and regulators alike.” He also added: “AI in compliance hold
Cardo AI Powers Multitude Bank’s Asset-Based Lending15.9.2025 09:21:00 EEST | Press release
Cardo AI, a leading technology platform for asset-based finance and private credit, today announced a strategic partnership with Multitude Bank p.l.c., a subsidiary of the listed Multitude AG. The collaboration will use Cardo AI’s platform to automate and streamline Multitude Bank’s asset-based lending (ABL) operations, enhancing efficiency and transparency in funding for small and medium-sized enterprises (SMEs). “Technology is the key to accelerating growth in asset-based credit,” said Altin Kadareja, Co-Founder & CEO of Cardo AI. “By automating and streamlining critical operations, our platform helps institutions like Multitude enhance the efficiency of their ABL businesses and provide faster, more flexible funding solutions to SMEs.” “Our clients expect both speed and reliability,” said Alain Nydegger, CEO of Wholesale Banking at Multitude Group. “By working with innovative technology partners, we can scale our asset-based lending operations more efficiently. Consolidating our ABL
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom